Background: The role of transbronchial needle aspiration (TBNA) in the diagnosis and staging of lung cancer has been well established. Recently, the efficacy of conventional TBNA in the staging of lung cancer has been enhanced by the use of endobronchial ultrasound (EBUS)-TBNA. Our study sought to evaluate the adequacy of TBNA of International Association for the Study of Lung Cancer (IASLC) stations 4R, 4L and 7 using endobronchial landmarks provided by the Wang nodal mapping system in the staging of lung cancer. Methods: We retrospectively analyzed all bronchoscopic cases with conventional TBNA punctures positive for malignancy at our institution from 1 January to 31 October 2014. The endobronchial puncture site was guided by the Wang nodal mapping system. The Wang stations were correlated with the IASLC lymph node map. No endobronchial ultrasound or rapid on-site evaluation was used. Pathological analysis included cytological and histological examination. Results: Diagnosis by histological analysis was obtained in 115 (55.3%) out of 208 puncture sites. The metastatic lymph nodes were distributed at IASLC stations 4R (W1, 3, 5) 46.6 %, 7 (W2, 8, 10) 19.7%, 4L (W4, 6) 11.5%, 11R (W7, W9) 11.1% 11L (W11) 9.6%, 2R (high station W3) 0.5%, and the proximal portion of station 8 (station W10 beyond the middle lobe orifice) 1%. No complications were observed. Conclusion: IASLC station 4R (W1, 3, 5), 7 (W2, 8, 10) and 4L (W4, 6) are adequate for the staging of lung cancer.
Introduction
Conventional transbronchial needle aspiration (C-TBNA) has been utilized for more than 30 years and has a wellestablished role in the diagnosis and staging of lung cancer. [1] [2] [3] [4] However, the variable sensitivity (37.0-94.7%) among operators has limited the adoption of this procedure for lung cancer staging. [5] [6] [7] In contrast, endobronchial ultrasound (EBUS)-TBNA has been demonstrated to be more reliable and has been recommended to aid the staging of lung cancer in recent years. 8, 9 Nonetheless, C-TBNA remains a popular procedure in countries with limited access to EBUS technologies. Improved methodologies of C-TBNA need to be implemented to improve its sensitivity, making it more acceptable for the general pulmonologist. 4, [10] [11] [12] Many factors may alter the sensitivity of TBNA, such as the experience of the bronchoscopists, which include technique skill and knowledge of the anatomy to appropriately selecting the puncture site. 4, 5, 10 The International Association for the Study of Lung Cancer (IASLC) and the Wang lymph node (LN) mapping system are crucial for the selection of the correct puncture site for TBNA and the staging of lung cancer. 3, [13] [14] [15] The aim of this study is to illustrate the efficacy and adequacy of C-TBNA using endobronchial landmarks for sampling of lymphadenopathy in the staging of lung cancer.
Material and methods
We retrospectively analyzed cases with C-TBNA punctures positive for malignancy from the Department of Respiratory Diseases, Shanxi Cancer Hospital, from bronchoscopies performed during the period 1 January to 31 October 2014. Only patients undergoing bronchoscopy for diagnosis and staging of lung cancer that had at least one diagnostic C-TBNA sample during the procedure were included in the study. The C-TBNA puncture sites were guided by the Wang map, computed tomography (CT) images, and endobronchial anatomical landmarks, and correlated to the IASLC nodal stations. 3 Correlation of the Wang and IASLC maps were performed as described in our previous work (Table 1 and Fig 1) . 16 Eleven stations in the Wang map were divided into three groups designated as right LN (station W1, 3, 5, 7, 9) , middle mediastinal LN (station W2, 8, 10) and left LN (station W4, 6, 11). Station W4 (A-P window) was classified as inner, middle, and outer windows, according to the distance from the LNs to the left edge of the trachea and ligamentum arteriosum. Except for station W7, 9, and 11, all others were considered mediastinal LNs based on their location and relationship with the IASLC map. C-TBNA for mediastinal staging was carried out according to institutional protocol (based on published criteria) in patients fulfilling one or more of the following criteria: (i) central tumor; (ii) enlarged (>10 mm) mediastinal LNs on CT; or (iii) positron emission tomography (PET)-positive mediastinal LNs. 17 EBUS and rapid on-site cytology evaluation were not available for these cases. All examinations were performed under topical anesthesia only. Cytologic needles (model 122; ConMed, Utica, NY, USA) were preferentially used during most procedures. Histologic needles (model 319; ConMed,) were occasionally used. Two or more aspirations were taken from all LN stations. Aspirated material was expelled onto glass slides and smeared for cytological examination, with or without core specimen and cellblock for histology.
Statistical analysis
Statistical analysis was performed using the Statistical Package for the Social Sciences v 21.0 (SPSS Inc., Chicago, IL, USA). Continuous variables were represented as mean and categorical variables and summarized as a percentage of the study population.
Results
A total of 208 C-TBNA punctures were positive for malignancy diagnosed by cytology or histology; 165 of these (79.3%) were considered to be mediastinal LNs according to IASLC and Wang definitions.
Core tissues and/or cellblock histologic diagnosis were obtained in 115 of 208 (55.3%) C-TBNA punctures positive for malignancy. The other 93 puncture sites were all diagnosed by cytology.
A total of 97 (46.6%) LNs were positive in station 4R (W1, 3, 5) (Fig 2) , 41 (19.7%) in station 7 (W2, 8, 10) (Fig 3) , 24 (11.5%) in station 4L (W4, 6) (Fig 4) , 23 (11.1%) in station 11R (W7, 9), 20 (9.6%) in station 11L (W11) (Fig 1) , 1 (0.5%) in station 2R (the high station W3), and 2 (1%) in the proximal portion of station 8 (distal portion of station W10) ( Table 1) .
No complications were reported in any of the cases.
Discussion
Whether utilizing C-TBNA or EBUS-TBNA, adequacy and efficacy are extremely important for the staging of lung cancer. Many recent reports have reported successful results using EBUS-TBNA for the staging of lung cancer. 8,9,18 EBUS (Fig 5) . Moreover, core tissues and a histology diagnosis were obtained in 115 (55.3%) cases, even with cytological needles preferentially used. No complications were demonstrated. Therefore, we conclude that C-TBNA can be adequately utilized in the staging of lung cancer.
Tucakovic and Wang reported the adequacy and efficacy of C-TBNA. 22 Rong et al. also found that TBNA puncture sites at the spaces equivalent to IASLC zone 2, 3, and 4 using Wang landmarks were highly accurate when later confirmed with EBUS. 23 Nearly 80% of the LN metastases were distributed at IASLC station 4R (W1, 3, 5), 4L (W4, 6) and 7 (W2, 8, 10), which were considered mediastinal LNs. Of 208 cases, only Exactly how to achieve consistent and efficacious results with C-TBNA for the staging of lung cancer needs to be discussed. First, how to find a correct puncture site for TBNA without EBUS is crucial. A clear understanding of the anatomy of intrathoracic LNs in relation to tracheobronchial landmarks plays an important role. This relationship may be enhanced by a careful pre-procedure review of available imaging, such as a CT scan. Second, the relationship between IASLC and Wang maps should also be emphasized in guiding selection to an ideal puncture site in the staging of lung cancer.
Although these hopeful and exciting results have suggested the efficacy and adequacy of C-TBNA of mediastinal and hilar lymphadenopathy for the staging of lung cancer, this study is limited by the retrospective design and the skills of the operator. A prospective study is needed to confirm these results.
Conclusion
In conclusion, C-TBNA is an effective, adequate, and safe procedure. Clear understanding of the anatomy of intrathoracic LNs in relation to endobronchial landmarks, as defined by the Wang map, is the key step for successful staging of lung cancer. Station 4R (W1, 3, 5), 4L (W4, 6), and 7 (W2, 8, 10) are usually effective and adequate for the staging of lung cancer by TBNA.
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